GOAL.MD Review
Best for: Patients comfortable with the Mimlitz disclosure who value manual-renewal billing + brand-name dose-tiered pricing transparency
Saint Louis, MO DTC telehealth (Jellyfish LLC, founded 2019) offering compounded personalized GLP-1 from $179/mo and brand bridges (Ozempic from $294/mo, Wegovy from $294/mo, Zepbound from $394/mo). LegitScript Certified, BBB A+ since 2021. Manual renewal — no auto-billing. CAUTION: Chief Physician & Co-Founder Dr. Michael 'Ted' Mimlitz pleaded guilty April 2016 in EDMO federal court to distributing misbranded HGH; Missouri Board revoked his license (reinstated on 2-year probation). No named pharmacy partner disclosed.
Low confidence · Last verified 2026-05-25 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
GOAL.MD is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
GOAL.MD prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Personalized (compounded, all doses) | compounded | $179 |
| Micro-Dose (compounded) | compounded | $197 |
| Oral pill | brand | $244 |
| 0.25-0.5 mg pen | brand | $294 |
| 1 mg pen | brand | $444 |
| 2 mg pen | brand | $594 |
| Pen (starter) | brand | $294 |
| Vial / KwikPen | brand | $394 |
✓ Pros
- •Transparent dose-tiered pricing on brand pens
- •LegitScript Certified
- •Manual-renewal model (no surprise auto-billing)
- •Free nutrition coach included
- •BBB A+ since 2021
✗ Cons
- •No named compounding pharmacy partner disclosed
- •Chief Physician & Co-Founder Dr. Ted Mimlitz has 2016 federal guilty plea for distributing misbranded HGH and Missouri medical-license revocation (reinstated on 2-year probation)
- •No URAC/PCAB pharmacy accreditation
Ready to start with GOAL.MD?
Starting at $179/month. See current pricing and start your free consultation.
Sources & methodology
Our GOAL.MD review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to GOAL.MD
Belle Health
Best for: Cost-sensitive patients comfortable with the Feb-2026 FDA warning, wanting flat-rate pricing and dietitian-included support
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with GOAL.MD?
Starting at $179/month. See current pricing and start your free consultation.